Immunosuppression in sepsis and possibility of its correction
https://doi.org/10.24884/0042-4625-2018-177-5-105-107
Abstract
Literature review is devoted to immunosuppression in sepsis and possibilities of its correction.
About the Authors
M. V. Kiselevskii
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Centre of Oncology», of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
S. M. Sitdikova
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Centre of Oncology», of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
A. G. Abdullaev
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Centre of Oncology», of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
S. A. Shlyapnikov
Federal State Budgetary Institution Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
St. Petersburg
I. O. Chikileva
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Centre of Oncology», of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Moscow
References
1. Targeting Immune Cell Checkpoints during Sepsis / N. K. Patil, Y. Guo, L. Luan, E. R. Sherwood // Int. J. Mol. Sci. 2017. Vol. 18, № 11. P. 2413.
2. Fleischmann C., Scherag A., Adhikari N. K. et al. International Forum of Acute Care Team. Assessment of Global incidence and mortality of hospital-treated sepsis. Current estimates and limitations // Am. J. Respir. Crit. Care Med. 2016. Vol. 193. P. 259–272.
3. Singer M., Deutschman C. S., Seymour C. W. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) // JAMA. 2016. Vol. 315. P. 801–810.
4. Hotchkiss R. S., Monneret G., Payen D. Immunosuppression in sepsis : a novel understanding of the disorder and a new therapeutic approach // Lancet Infect Dis. 2013. Vol. 13, № 3. P. 260–268.
5. Boomer J. S., Green J. M., Hotchkiss R. S. The changing immune system in sepsis : is individualized immuno-modulatory therapy the answer? // Virulence. 2014. Vol. 5, № 1. P. 45–56.
6. Gentile L. F., Cuenca A. G., Efron P. A. et al. Persistent inflammation and immunosuppression : A common syndrome and new horizon for surgical intensive care // J. Trauma Acute Care Surg. 2012. Vol. 72. P. 1491–1501.
7. Hotchkiss R. S., Karl I. E. The pathophysiology and treatment of sepsis // N. Engl. J. Med. 2003. Vol. 348, № 2. P. 138–150.
8. Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lancet Infect Dis. 2012. Vol. 12. № 7. P. 503–505.
9. Benchmarking the incidence and mortality of severe sepsis in the United States / D. F. Gaieski, J. M. Edwards, M. J. Kallan, B. G. Carr // Critical care medicine. 2013. Vol. 41, № 5. P. 1167–1174.
10. Delano M. J., Ward P. A. Sepsis-induced immune dysfunction: Can immune therapies reduce mortality? // J. Clin. Investig. 2016. Vol. 126. P. 23–31.
11. Walton A. H., Muenzer J. T., Rasche D. et al. Reactivation of multiple viruses in patients with sepsis // PLoS ONE. 2014. Vol. 9. P. e98819.
12. Hotchkiss R. S., Sherwood E. R. Immunology. Getting sepsis therapy right // Science. 2015. Vol. 347. P. 1201–1202.
13. ICU-acquired immunosuppression and the risk for secondary fungal infections / G. Monneret, F. Venet, B. J. Kullberg, M. G. Netea // Med. Mycol. 2011. Vol. 49, Suppl. 1. P. S17–S23.
14. Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.
15. Boomer J. S., To K., Chang K. C. et al. Immunosuppression in patients who die of sepsis and multiple organ failure // Jama. 2011. Vol. 306, № 23. P. 2594–2605.
16. Ayala A., Herdon C. D., Lehman D. L. et al. The induction of accelerated thymic programmed cell death during polymicrobial sepsis : control by corticosteroids but not tumor necrosis factor // Shock. 1995. Vol. 3, № 4. P. 259–267.
17. Cohen J., Opal S., Calandra T. Sepsis studies need new direction // Lan cet Infect Dis. 2012. Vol. 12, № 7. P. 503–505.
18. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo / M. A. Williams, S. Withington, A. C. Newland, S. M. Kelsey // The Journal of infectious diseases. 1998. Vol. 178, № 5. Р. 1421–1433.
19. Fan X., Liu Z., Jin H. et al. Alterations of dendritic cells in sepsis : featured role in immunoparalysis // BioMed Research International. 2015. Vol. 2015. ID 903720.
20. Otto G. P., Sossdorf M., Claus R. A. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate // Critical care. 2011. Vol. 15, № 4. P. R183.
21. Venet F., Chung C. S., Kherouf H. et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (−)) contribute to lymphocyte anergy in septic shock patients // Intensive care medicine. 2009. Vol. 35, № 4. P. 678–686.
22. Drewry A. M., Samra N., Skrupky L. P. et al. Persistent Lymphopenia after Diagnosis of Sepsis Predicts Mortality // Shock. 2014. Vol. 42, № 5. Р. 383–391.
23. Nalos M., Santner-Nanan B., Parnell G. et al. Immune effects of interferon gamma in persistent staphylococcal sepsis // Am. J. Respir. Crit. Care Med. 2012. Vol. 185, № 1. P. 110–112.
24. Levy Y., Sereti I., Tambussi G. et al. Effects of recombinant human inter leukin 7 on T-cell recovery thymic output in HIV-infected patients re cei ving antiretroviral therapy : results of a phase I/IIa randomized placebo-controlled multicenter study // Clin. Infect Dis. 2012. Vol. 55, № 2. P. 291–300.
25. Guo Y., Luan L., Rabacal W. et al. IL-15 Superagonist-Mediated Immunotoxicity : Role of NK Cells and IFN-gamma // Journal of immunology. 2015. Vol. 195, № 5. P. 2353–2364.
26. Conlon K. C., Lugli E., Welles H. C. et al. Redistribution hyperproliferation activation of natural killer cells CD8 T cells and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer // Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Vol. 33, № 1. P. 74–78.
27. Anisimov A. Yu. Immunoterapiya ronkolejkinom v kompleksnom lechenii bol’nyh abdominal’nym sepsisom / Kazanskaya gosudarstvennaya medicinskaya akademiya Minzdra va Rossii. Kazan’, 2004. 28 p.
28. Lebedev V. F., Gavrilin S. V., Kozlov V. K. Immunoprofilaktika i operezhayushchaya terapiya posttravmaticheskogo sepsisa drozhzhevym rekombinantnym interlejkinom-2 // Citokiny i vospalenie. 2002. Vol. 1, № 2. P. 46–47.
29. Lebedev M. F., Gavrilin S. V., Kozlov V. K., Egorova V. N. Opyt primeneniya Ronkolejkina v rannem periode travmaticheskoj bolezni // Terra Medica. 2001. № 3. P. 35–37.
30. Gavrilin S. V., Kozlov V. K., Lebedev V. F. Immunopatogenez tyazhelyh ranenij i travm : vozmozhnosti immunokorrekcii // Vestnik khirurgii im. I. I. Grekova. 2002. № 4. P. 85–90.
31. Patera A. C., Drewry A. M., Chang K. et al. Frontline Science : Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 // J. Leukoc. Biol. 2016. Vol. 100. P. 1239–1254.
Review
For citations:
Kiselevskii M.V., Sitdikova S.M., Abdullaev A.G., Shlyapnikov S.A., Chikileva I.O. Immunosuppression in sepsis and possibility of its correction. Grekov's Bulletin of Surgery. 2018;177(5):105-107. (In Russ.) https://doi.org/10.24884/0042-4625-2018-177-5-105-107
Views:
892
Email this article 